4月15日,ADC明星企业映恩生物-B(09606.HK)正式登陆港交所。截至发稿,映恩生物报205港元/股,涨幅116.7%。映恩生物IPO发行定价为94.6港元/股,认购情况火爆,募资总额约2.1亿美元(约合人民币15.4亿元),这是自2022年来募资规模最大的港股18A企业。(时代财经李傲华)
(文章来源:时代财经)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.